Saturday 17 October 2026
Export CVRX’s income statement to Excel — free account
CVRx, Inc.
CVRX Healthcare Medical Devices
CVRx, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $56.7 million, up 10.4% from fiscal 2024. In the quarter to June 2026, revenue grew 15.6%, EPS grew 7.02%, free cash flow fell 11.2% and total debt rose 18.6%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
1.30
0.09
−6.47%
Follow CVRX
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
4 | 2 | 3 | 3 | 3 | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Altman Z-Score |
(6.26) | (2.90) | 4.36 | 9.62 | 8.58 | — | — | — |
P/S ratio |
3.27 | 5.58 | 16.10 | 17.12 | 9.72 | 1.25 | 1.25 | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Altman Z″-Score (non-manufacturers) |
(15.50) | (9.08) | (8.06) | (0.37) | 19.92 | (11.81) | (38.89) | — |
Beneish M-Score |
(3.03) | (3.25) | (1.42) | 4.17 | (1.82) | (1.70) | — | — |
P/Operating CF |
(18.98) | (35.75) | (80.72) | (35.47) | (18.06) | (1.59) | (1.59) | — |
P/B ratio |
4.71 | 4.03 | 8.33 | 3.52 | 0.87 | 0.00 | 0.00 | — |
Price to Tangible BV |
4.71 | 4.03 | 8.33 | 3.52 | 0.87 | 0.00 | 0.00 | — |
EV/Sales |
2.87 | 4.54 | 14.63 | 12.84 | 0.32 | (2.12) | (2.12) | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.11 | 1.11 | — |
EV/Operating CF |
(4.04) | (5.95) | (14.73) | (6.76) | (0.15) | 0.84 | 0.84 | — |
EV/FCF |
(3.98) | (5.75) | (14.51) | (6.65) | (0.14) | 0.81 | 0.81 | — |
Quick Ratio |
6.49 | 10.70 | 12.48 | 13.81 | 24.48 | 7.57 | 3.07 | — |
Current Ratio |
7.63 | 12.06 | 14.25 | 15.19 | 25.58 | 8.07 | 3.36 | — |
Net Debt/EBITDA |
0.52 | 0.97 | 1.45 | 2.36 | 5.56 | 3.57 | (26.95) | — |
Debt/Assets |
47.25% | 36.93% | 25.36% | 5.40% | 0.00% | 29.76% | 1,027.16% | 0.00% |
Debt/Equity |
1.26 | 0.69 | 0.38 | 0.06 | 0.00 | 0.52 | (1.07) | — |
Asset Turnover |
0.48 | 0.41 | 0.33 | 0.16 | 0.12 | 0.13 | 0.43 | — |
Operating CF/Net income |
0.75 | 0.65 | 0.95 | 1.03 | 0.64 | 1.12 | 0.87 | — |
Capex/Depreciation |
(0.58) | (1.66) | (0.87) | (1.57) | (2.98) | (0.86) | 0.00 | — |
Interest Coverage |
(8.80) | (13.53) | (23.96) | (257.74) | (11.70) | (4.66) | (11.85) | — |
| (96.59%) | (81.58%) | (44.51%) | (32.47%) | 58.50% | 5.01% | 5.12% | — | |
| (44.76%) | (48.23%) | (34.31%) | (29.86%) | (39.64%) | (30.52%) | (100.64%) | — | |
ROIC |
(244.03%) | (258.29%) | (184.52%) | (273.09%) | (417.55%) | 0.00% | 0.00% | — |
Return on Tangible Assets |
(58.85%) | (49.33%) | (38.87%) | (35.56%) | (29.38%) | (25.23%) | (71.56%) | — |
Average Days of Receivables |
68.71 | 65.95 | 70.14 | 89.41 | 71.68 | 77.25 | 41.94 | — |
Research and Development Expense of Revenue |
19.65% | 21.70% | 29.60% | 44.29% | 57.54% | 105.90% | 138.44% | — |
Selling, General and Administrative Expense of Revenue |
156.17% | 178.03% | 164.17% | 222.73% | 213.74% | 160.53% | 96.69% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
19.51% | 37.14% | 16.04% | 17.30% | 14.67% | 2.18% | 0.00% | — |
Graham Net Nets |
0.20 | 0.24 | 0.12 | 0.28 | 1.14 | 1.00 | 1.00 | — |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Earnings Yield |
(28.87%) | (21.23%) | (6.49%) | (10.78%) | (598.67%) | (326.95%) | (326.95%) | — |
Free Cash Flow Yield |
(22.00%) | (14.15%) | (6.26%) | (11.28%) | (22.82%) | (209.17%) | (209.17%) | — |
Revenue per Share |
2.17 | 2.27 | 1.89 | 1.09 | 1.26 | 15.64 | 0.32 | — |
Operating CF per Share |
(1.54) | (1.73) | (1.88) | (2.08) | (2.68) | (41.59) | (0.66) | — |
Capex per Share |
(0.02) | (0.06) | (0.03) | (0.03) | (0.11) | (0.80) | 0.00 | — |
Free Cash Flow per Share |
(1.56) | (1.79) | (1.91) | (2.11) | (2.79) | (42.40) | (0.66) | — |
Cash per Share |
2.90 | 4.69 | 4.36 | 5.17 | 13.71 | 152.74 | 1.33 | — |
Shareholders Equity per Share |
1.51 | 3.14 | 3.66 | 5.32 | 14.09 | 94.95 | (14.46) | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
1.51 | 3.14 | 3.66 | 5.32 | 14.09 | 94.95 | (14.46) | — |
Free Cash Flow |
(40.75) | (40.50) | (39.61) | (43.36) | (28.91) | (16.41) | (12.78) | — |
Working Capital |
88.33 | 119.05 | 104.23 | 114.79 | 145.19 | 56.36 | 20.29 | — |
Capital Expenditures |
(0.58) | (1.36) | (0.59) | (0.68) | (1.18) | (0.31) | (0.11) | — |
Net Current Asset Value |
36.18 | 67.45 | 72.81 | 107.12 | 144.51 | 36.31 | (279.24) | — |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.09 | 1.09 | — |
Capex to Sales |
0.01 | 0.03 | 0.02 | 0.03 | 0.09 | 0.05 | 0.00 | — |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Other line items | ||||||||
Depreciation/Fixed assets |
0.44 | 0.33 | 0.38 | 0.26 | 0.28 | 0.88 | 0.32 | — |
Cash ROIC |
(24.77%) | (17.90%) | (20.24%) | (19.52%) | (10.04%) | (14.25%) | (27.99%) | — |
Accounts Receivable Turnover |
5.68 | 6.10 | 6.02 | 5.57 | 6.79 | 6.05 | 6.26 | — |
Accounts Payable Turnover |
2.59 | 3.73 | 3.47 | 4.49 | 7.33 | 3.13 | 3.78 | — |
Inventory Turnover |
0.68 | 0.72 | 0.70 | 0.92 | 1.01 | 0.53 | 0.64 | — |
Average Days of Payables |
168.34 | 113.08 | 109.92 | 125.51 | 51.14 | 122.43 | 91.72 | — |
Days of Inventory on Hand |
536.02 | 530.24 | 640.79 | 507.96 | 389.07 | 847.36 | 434.89 | — |
Average Receivables |
9.97 | 8.41 | 6.53 | 4.03 | 1.92 | 1.00 | 1.00 | — |
Average Payables |
3.21 | 2.23 | 1.80 | 1.11 | 0.50 | 0.46 | 0.46 | — |
Average Inventory |
12.16 | 11.55 | 8.97 | 5.42 | 3.61 | 2.71 | 2.71 | — |
Average Assets |
119.10 | 124.32 | 120.08 | 138.74 | 108.66 | 46.94 | 14.55 | — |
Average Common Equity |
55.19 | 73.50 | 92.56 | 127.57 | (73.64) | (286.14) | (286.14) | — |
Columns are period end dates